Literature DB >> 8879230

Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice.

I Screpanti1, P Musiani, D Bellavia, M Cappelletti, F B Aiello, M Maroder, L Frati, A Modesti, A Gulino, V Poli.   

Abstract

Castleman's disease is a lymphoproliferative disorder thought to be related to deregulated production of IL-6. We have previously shown that mice lacking the trans-acting factor C/EBP beta, a transcriptional regulator of IL-6 and a mediator of IL-6 intracellular signaling, develop a pathology nearly identical to multicentric Castleman's disease, together with increasingly high levels of circulating IL-6. We describe here how the simultaneous inactivation of both IL-6 and C/EBP beta genes prevents the development of pathological traits of Castleman's disease observed in C/EBP beta-deficient mice. Histological and phenotypic analysis of lymph nodes and spleen of double mutant mice did not show either the lymphoadenopathy and splenomegaly or the abnormal expansion of myeloid, B and plasma cell compartments observed in C/EBP beta-/- mice, while B cell development, although delayed, was normal. Our data demonstrate that IL-6 is essential for the development of multicentric Castleman's disease in C/EBP beta-/- mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879230      PMCID: PMC2192807          DOI: 10.1084/jem.184.4.1561

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors:  X G Zhang; B Klein; R Bataille
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

Review 2.  Multicentric Castleman's disease.

Authors:  B A Peterson; G Frizzera
Journal:  Semin Oncol       Date:  1993-12       Impact factor: 4.929

3.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Authors:  J T Beck; S M Hsu; J Wijdenes; R Bataille; B Klein; D Vesole; K Hayden; S Jagannath; B Barlogie
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

4.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

Authors:  S J Brandt; D M Bodine; C E Dunbar; A W Nienhuis
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

5.  IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP.

Authors:  V Poli; F P Mancini; R Cortese
Journal:  Cell       Date:  1990-11-02       Impact factor: 41.582

Review 6.  Biological and clinical aspects of interleukin 6.

Authors:  T Hirano; S Akira; T Taga; T Kishimoto
Journal:  Immunol Today       Date:  1990-12

7.  Impaired immune and acute-phase responses in interleukin-6-deficient mice.

Authors:  M Kopf; H Baumann; G Freer; M Freudenberg; M Lamers; T Kishimoto; R Zinkernagel; H Bluethmann; G Köhler
Journal:  Nature       Date:  1994-03-24       Impact factor: 49.962

8.  Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20.

Authors:  D Roulston; R Espinosa; M Stoffel; G I Bell; M M Le Beau
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

9.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

10.  Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice.

Authors:  I Screpanti; L Romani; P Musiani; A Modesti; E Fattori; D Lazzaro; C Sellitto; S Scarpa; D Bellavia; G Lattanzio
Journal:  EMBO J       Date:  1995-05-01       Impact factor: 11.598

View more
  22 in total

1.  Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways.

Authors:  Jianping Xie; Hongyi Pan; Seungmin Yoo; Shou-Jiang Gao
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 3.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

4.  Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis.

Authors:  E Sterneck; S Zhu; A Ramirez; J L Jorcano; R C Smart
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

5.  C19ORF66 Broadly Escapes Virus-Induced Endonuclease Cleavage and Restricts Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  William Rodriguez; Kumaraman Srivastav; Mandy Muller
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

6.  A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.

Authors:  Margaret E Tome; David B F Johnson; Lisa M Rimsza; Robin A Roberts; Thomas M Grogan; Thomas P Miller; Larry W Oberley; Margaret M Briehl
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

7.  Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta are protected against diet-induced obesity.

Authors:  Carrie A Millward; Jason D Heaney; David S Sinasac; Eric C Chu; Ilya R Bederman; Danielle A Gilge; Stephen F Previs; Colleen M Croniger
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

Review 8.  IL-6 as a keystone cytokine in health and disease.

Authors:  Christopher A Hunter; Simon A Jones
Journal:  Nat Immunol       Date:  2015-05       Impact factor: 25.606

Review 9.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

10.  Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines.

Authors:  Yong-Chen Lu; Ira Kim; Elizabeth Lye; Fang Shen; Nobutaka Suzuki; Shinobu Suzuki; Steve Gerondakis; Shizuo Akira; Sarah L Gaffen; Wen-Chen Yeh; Pamela S Ohashi
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.